Cargando…
Beta-blocker under-use in COPD patients
BACKGROUND: Cardiovascular (CVS) comorbidities are common in COPD and contribute significantly to morbidity and mortality, especially following acute exacerbations of COPD (AECOPD). Beta-blockers (BBs) are safe and effective in COPD patients, with demonstrated survival benefit following myocardial i...
Autores principales: | Lim, Kuan Pin, Loughrey, Sarah, Musk, Michael, Lavender, Melanie, Wrobel, Jeremy P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655126/ https://www.ncbi.nlm.nih.gov/pubmed/29089752 http://dx.doi.org/10.2147/COPD.S144333 |
Ejemplares similares
-
Beta-blocker use and COPD mortality: a systematic review and meta-analysis
por: Etminan, Mahyar, et al.
Publicado: (2012) -
Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD
por: Huang, Yueh Lan, et al.
Publicado: (2017) -
Who's Afraid of the Big Bad Wolf? Safety of Beta-Blockers in COPD
por: Ambrosio, Giuseppe, et al.
Publicado: (2019) -
Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD
por: van Gestel, Yvette RBM, et al.
Publicado: (2009) -
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)